Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 4/20 | 0.40 |
| ▸ | BCL9 | O00512 | 2/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364049 | 1.00 | GSK3B (0.44) | GSK3BDYRK1AMAP2K1TBK1HTR2C | |
| SCHEMBL25029253 | 0.89 | BCL9 (0.46) | GSK3BDYRK1ATBK1BCL9CTNNB1 | |
| Formic Acid SCHEMBL29005526 | 0.84 | BCL9 (0.46) | GSK3BDYRK1ATBK1BCL9CTNNB1 | |
| Formic Acid SCHEMBL29361291 | 0.84 | BCL9 (0.46) | GSK3BDYRK1ATBK1BCL9CTNNB1 | |
| SCHEMBL29362012 | 0.83 | GSK3B (0.47) | GSK3BDYRK1AMAP2K1TBK1HTR2C | |
| SCHEMBL25029240 | 0.83 | GSK3B (0.47) | GSK3BDYRK1AMAP2K1TBK1HTR2C | |
| SCHEMBL25029276 | 0.79 | HTR1A (0.47) | DYRK1AHTR2CHTR2BBCL9CTNNB1 | |
| SCHEMBL29363789 | 0.79 | HTR1A (0.47) | DYRK1AHTR2CHTR2BBCL9CTNNB1 | |
| SCHEMBL25029015 | 0.79 | GSK3B (0.47) | GSK3BDYRK1ATBK1HTR2CHTR2B | |
| SCHEMBL26180176 | 0.79 | GSK3B (0.47) | GSK3BDYRK1ATBK1BCL9CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4182320-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| CN-115996926-A | Indole compounds as androgen receptor modulators | 尼多生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GSK3B 463/4885DYRK1A 1187/4885MAP2K1 2766/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | GSK3B 441/4885DYRK1A 1097/4885MAP2K1 2715/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | GSK3B 468/4885DYRK1A 937/4885MAP2K1 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.